The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

Press releases published on July 28, 2026

Jul. 28, 2026

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

Indeterminate GlobeNewswire

Jul. 28, 2026

Lifecore Biomedical Signs Three New Customer Agreements

Indeterminate GlobeNewswire

Jul. 28, 2026

Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687

Indeterminate GlobeNewswire

Jul. 28, 2026

NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

Indeterminate GlobeNewswire

Jul. 28, 2026

Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration

Indeterminate GlobeNewswire

Jul. 28, 2026

Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients

Indeterminate GlobeNewswire

Jul. 28, 2026

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Indeterminate GlobeNewswire

Jul. 28, 2026

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Indeterminate GlobeNewswire

Jul. 28, 2026

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Indeterminate GlobeNewswire

Jul. 28, 2026

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Indeterminate GlobeNewswire

Jul. 28, 2026

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Indeterminate GlobeNewswire

Jul. 28, 2026

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Indeterminate GlobeNewswire

Jul. 28, 2026

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

Indeterminate GlobeNewswire

Jul. 28, 2026

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

Indeterminate GlobeNewswire

Jul. 28, 2026

Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch

Indeterminate GlobeNewswire

Jul. 28, 2026

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

Indeterminate GlobeNewswire

Jul. 28, 2026

Aqua free unterstützt Trinkwasserprojekt in Tansania

Indeterminate GlobeNewswire

Jul. 28, 2026

Aqua free Supports Drinking Water Project in Tanzania

Indeterminate GlobeNewswire

Jul. 28, 2026

Aqua free soutient un projet d’accès à l’eau potable en Tanzanie

Indeterminate GlobeNewswire

Jul. 28, 2026

Tensive reports pivotal 12-month clinical trial data confirming REGENERA™ delivers natural breast reconstruction after lumpectomy

Indeterminate GlobeNewswire